SWISS INNOVATION APPLIED TO BEAUTY · † 5 visits: injection on day 1, check-up at 15 days, 1...
Transcript of SWISS INNOVATION APPLIED TO BEAUTY · † 5 visits: injection on day 1, check-up at 15 days, 1...
S W I S S I N N O V A T I O N A P P L I E D T O B E A U T Y
RÉ
F: 5
0014
5 -
CO
NC
EP
TIO
N :
LE
MA
HIE
U D
ES
IGN
www.teoxane.com
A different gel designedfor Eye Circles
Redensity TEOSYAL PURESENSE
EyesEyes
INNOVATION
TEOXANE
LA B O R AT O R I ES
MEDECIN REDENSITY II GB.indd 1MEDECIN REDENSITY II GB.indd 1 21/12/12 11:1821/12/12 11:18
ANATOMICAL AND HISTOLOGICAL LANDMARKS
EYES CIRCLES,A DELICATE AREA
Fine skin, low level of hyaluronidase 1
Supraorbicular fat2
Orbicular muscle3
Suborbital fat (SOOF)4
Periosteum5
Palpebral line0
Tear trough1
Palpebromalar groove2
Mediojugal fold3
Nasolabial fold4
ANATOMICAL SPECIFICITIES OF THE SUBORBITAL AREA
A complex lymphatic system High risk areas : Angular artery Emergence of the infraorbital nerve V2
So
urce
: R
alf
J. R
adla
nski
& k
arl H
.Wes
ker
- D
as G
esic
ht B
ildat
las
klin
isch
e A
nato
mie
Teo
xane
dat
a so
urce
Teo
xane
dat
a so
urce
Teo
xane
dat
a so
urce
1
2
1
2
Eyes
MEDECIN REDENSITY II GB.indd 2MEDECIN REDENSITY II GB.indd 2 21/12/12 11:1821/12/12 11:18
2
A DIFFERENT GEL DESIGNED TO TREAT EYE CIRCLES FOR A NATURAL AND LONG LASTING CORRECTION
A SUBTLE BALANCE BETWEEN A LOW LEVEL OF HAAND A SEMI-CROSSLINKED HA: A LOW HYGROSCOPIC ACTIVITY• To reduce the risk of oedema and swelling with a quantity < 0.5ml by eye circle.(3)
A LIGHT GEL WHICH EXERTS LOW PRESSURE ON THE TISSUES • To reduce risk of oedema.(3)
A SOPHISTICATED AND SYNERGISTIC 3-IN-1 FORMULA,COMBINING NATURAL INGREDIENTS
DERMO-RESTRUCTURINGCOMPLEX (2)
8 amino acids: Glycine, Lysine, Threonine,Proline, Isoleucine, Leucine, Valine, Arginine
3 antioxydants: Glutathion,N-Acetyl-L-cysteine, Alphalipoic acid
2 minerals: Zinc and Copper1 vitamin: B6
LIDOCAINE
SEMI-CROSSLINKEDHYALURONIC ACID (HA)
15 mg/g Mix of cross-linked (1) HA (BDDE)
and non cross-linked HA
AN IDEAL VISCOELASTICITY: HIGH SPREADING CAPABILITY• To maximise the ease of injection (81%*) and positioning (100%*).(3)
Gel n°1: cross-linked HA24mg/g Teosyal® PureSense Redensity [II] Gel n°2: cross-linked HA
20mg/g
Photos: Teoxane data source
Redensity TEOSYAL PURESENSE
EyesEyes
(1) From the patented technology RHA: Resilient Hyaluronic Acid™
(2) Patent pending technology
(3) Phase III multicentric clinical study of 67 patients followed during 1 year (2010)
* Practitioners evaluation
MEDECIN REDENSITY II GB.indd 3MEDECIN REDENSITY II GB.indd 3 21/12/12 11:1821/12/12 11:18
So
urce
: R
alf
J. R
adla
nski
& k
arl H
.Wes
ker
- D
as G
esic
ht B
ildat
las
klin
isch
e A
nato
mie
Eyes
(1) Phase III multicentric clinical study of 67 patients followed during 1 year (2010)
* GAIS : Global Aesthetic Improvement Scale
SAFETY AND EFFICACY RESULTS – PHASE III STUDY (1)
Redensity TEOSYAL PURESENSE
EyesEyes
CLINICAL PROTOCOL• Multicentric clinical trial held by 6 practitioners with 67 patients
• Follow-up: 1 year
• 5 visits: injection on day 1, check-up at 15 days, 1 month, 3 months, 6 months and 12 months
• GAIS* cross-evaluation
• No touch-up in 72% of cases. Touch-up only for patients injected with 0.2 ml at first
EFFICIENCY RESULTS
Teo
xane
dat
a so
urce
BEFORE
Teo
xane
dat
a so
urce
AFTERImmediate result after injection
- Indications: tear trough deformity
- Injected volume: 0.15 ml on right side and 0.20 ml on left side
- Slow injection
• PATIENT N° 1
BEFOREAFTER
Immediate result after injection
Teo
xane
dat
a so
urce
Teo
xane
dat
a so
urce
- Indications: tear trough deformity and Palpebromalar groove
- Injected volume: 0.20 ml per side
- Slow injection
• PATIENT N° 2
MEDECIN REDENSITY II GB.indd 4MEDECIN REDENSITY II GB.indd 4 21/12/12 11:1821/12/12 11:18
SAFETY AND EFFICACY RESULTS – PHASE III STUDY (1)
Redensity TEOSYAL PURESENSE
EyesEyes
(1) Phase III multicentric clinical study of 67 patients followed during 1 year (2010)
* GAIS : Global Aesthetic Improvement Scale
Eyes
HIGH DEGREE OF SATISFACTION :PATIENTS AND PRACTITIONERS EVALUATION
RECOGNIZED TOLERANCE OVER 1 YEAR • The safety of Teosyal® PureSense Redensity [II] was demonstrated with an average injected volume of 0.37 ml per eye circle
• Out of 67 patients: - 4 cases of transitional side effects were noted. Redness and post-injection bruising disappeared within 72h after injection
- 1 single case of oedema was observed. The oedema resorbed spontaneously in less than 1 month (0.6ml injected)
- No tyndall effect was observed
The majority of patients were satisfied with the results immediately after injection, at month-6 and month-12 and would recommend it to their relatives. (1)
Evaluation of the overall aesthetic results by the practitioner and the patient (Percentage of improvement - calculated from the GAIS*)
Immediately afterinjection
Month-1 Month-3 Month-6 Month-120%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
% o
f im
pro
vem
ent
No
n e
valu
ated
Practitioners Patients
MEDECIN REDENSITY II GB.indd 5MEDECIN REDENSITY II GB.indd 5 21/12/12 11:1821/12/12 11:18
Eyes
APPROPRIATE DIAGNOSIS OF EYE CIRCLES FOR OPTIMAL EFFICACY AND TOLERABILITY• Sit the patient for diagnosis and evaluation in a semi-reclined position
• Exert a slight pressure on the eye before the injection to help:
- Determine the orbital margin
- Detect any lymphatic insufficiency
• Perform a snap test to ensure there is no excessive palpebral looseness
Teo
xane
dat
a so
urce
TEOSYAL® PURESENSEREDENSITY [II] INDICATIONS • Eye Circles
• Tear trough
• Palpebromalar groove
• Minimal palpebral or malar bags
For malar and jugal area, use more volumising fillers
WRONG INDICATIONS • Exclusively pigmentary dark circles
• Large palpebral or malar bags
Pho
tos:
S. P
oig
none
c (F
ranc
e)
Teo
xane
dat
a so
urce
Pho
tos:
S. P
oig
none
c (F
ranc
e)
Pigmentary dark circles Large palpebral bags
DIAGNOSIS: AN ESSENTIAL STEP
Redensity TEOSYAL PURESENSE
EyesEyes
MEDECIN REDENSITY II GB.indd 6MEDECIN REDENSITY II GB.indd 6 21/12/12 11:1821/12/12 11:18
Redensity TEOSYAL PURESENSE
EyesEyesEyes
A PRECISE INJECTION TECHNIQUE
PROTOCOL• First session: under correction is recommended
• Touch-up session: 1 month later, only if necessary
TEOSYAL® PURESENSE REDENSITY [II]• Package: 2 x 1ml
• CE marking: class III
RECOMMENDED DOSE• Quantity for each eye circle < 0.5ml:
To obtain maximum safety and good long-term results, it is strongly recommended not to inject more than 0.5 ml of Teosyal® PureSense Redensity [II] in each eye circle
INJECTION TECHNIQUES• Slow injection
• Deep supra-periosteal
• Sub-orbicular
Retrograde techniquewith cannula
Microbolus techniquewith needle
Teo
xane
dat
a so
urce
Teo
xane
dat
a so
urce
High risk area : emergence of the infra orbital nerve V2 High risk area : emergence of the infra orbital nerve V2
MEDECIN REDENSITY II GB.indd 7MEDECIN REDENSITY II GB.indd 7 21/12/12 11:1921/12/12 11:19
S W I S S I N N O V A T I O N A P P L I E D T O B E A U T Y
Les Charmilles - Rue de Lyon, 105 - CH 1203 Genève
Tél. : +41 (0) 22 344 96 36 - Fax : +41 (0) 22 340 29 33
General information: [email protected]
Medical information department: [email protected]
www.teoxane.com RÉ
F: 5
0014
5 -
CO
NC
EP
TIO
N :
LE
MA
HIE
U D
ES
IGN
Eyes
INNOVATION
TEOXANE
LA B O R AT O R I ES
MEDECIN REDENSITY II GB.indd 8MEDECIN REDENSITY II GB.indd 8 21/12/12 11:1921/12/12 11:19